| |
 |
This is the category page. Below are all of the research programs that are associated with it
- Children receiving Cisplatin-
COG #ACCL0431, A RANDOMIZED PHASE III STUDY OF SODIUM THIOSULFATE FOR THE PREVENTION OF CISPLATIN-INDUCED OTOTOXICITY IN CHILDREN
(1_20081207_118)
This is a multicenter study for participants receiving cisplatin. Participants are randomized to 1 of 2 arms. After completion of study treatment, participants are followed periodically for 10 years. Arm 1 is drug therapy and participants will receive sodium thiosulfate IV over 15 minutes beginning 6 hours after the completion of each cisplatin infusion. Treatment with sodium thiosulfate continues until the completion of cisplatin therapy. Arm II is an observational arm and participants do not receive sodium thiosulfate. All participants will have hearing tests before treatments start, prior to each course of cisplatin, and then at 4 weeks and again at 1 year after the last course of cisplatin or other cancer treatment.
- Children receiving Cisplatin-
COG #ACCL05C1, A GROUP-WIDE, PROSPECTIVE STUDY OF OTOTOXICITY ASSESSMENT IN CHILDREN RECEIVING CISPLATIN CHEMOTHERAPY
(1_20081206_118)
This is a multicenter, prospective, cohort study. Patients undergo hearing tests (conventional, otoscopy, ultrahigh frequency, and otoacoustic emission testing) before the first course of planned cisplatin, before each subsequent course of cisplatin, and 4 weeks after the last dose of cisplatin. Patients who are scheduled to receive hematopoietic progenitor stem cell transplantation undergo hearing tests before the transplantation and 4 weeks after transplantation.
- End of Life Cancer Care -
A COMPUTER-BASED DECISION AID FOR HEALTH CARE DECISION MAKING
(2_20080908_118)
This is a randomized trial comparing a computer-based decision aid for advance care planning with the standard advance care planning in the form of a paper “Living Will” for use with patients with cancer. Participants will be randomly assigned to complete either the computer version or the paper version. Study personnel will telephone participants every six weeks after completion of the study document to determine whether or not they have discussed their advance directive with family and/or health care providers and assess the relationship between the patient and their healthcare provider. The study team will be notified within 48 hours of the patients passing away to interview either the physician or hospice worker; and to interview a family member within 6 weeks of death to see how the patients end-of-life wisher were carried out.
- Fatigure - Cancer Related -
NCCTG #N07C2: THE USE OF WISCONSIN GINSENG (PANAX QUINQUEFOLIUS) TO IMPROVE CANCER-RELATED FATIGUE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY
(1_20090105_118)
This is a multicenter, interventional, supportive care, randomized, double-blind, placebo control study. Patients are assigned to each arm according to baseline fatigue. Participants on Arm 1 will receive oral American ginseng twice a day for 14 days. This treatment will repeat every 2 weeks for 4 courses or until disease progression or unacceptable side effects. Participants on Arm II will receive oral placebo twice a day for 14 days. This treatment will repeat every 2 weeks for 4 courses also. Participants will need to complete a diary and questionnaires weekly. Patients who are not actively receiving chemotherapy or radiation therapy will need to undergo blood and saliva sample collection at beginning of the study and periodically during study for correlative studies.
- Hodgkin Disease in Children -
COG #AHOD04B1: HODGKIN DISEASE (HD) BANKING STUDY
(1_20081108_118)
This study is a registry and specimen collection study. This study is designed to better understand why some people get Hodgkin Disease, and why there is a difference in therapy response, recurrence and complications. Tumor samples will be obtained with the initial diagnostic biopsy and/or at the time of relapse. A total of approximately one to four tablespoons of blood will be taken at various time points during and after treatment.
- Neuropathy -
NCCTG #N05C3: THE USE OF VITAMIN E FOR PREVENTION OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY: A PHASE III DOUBLE-BLIND PLACEBO CONTROLLED STUDY (2_20070210_118)
This study is a Phase II, double-blind placebo controlled study for the use of Vitamin E for the prevention of chemotherapy induced peripheral neuropathy. Participants will be randomized to one of two arms of the study. One group will receive Vitamin E – 2 capsules - 300 mg starting within 4 days of 1st chemo treatment; and the other group will receive Placebo – 2 capsules within 4 days of 1st chemo treatment. Participants will continue throughout the time of their treatment of chemotherapy and one month after stopping chemotherapy. The cycle length will be according to that of the length for the chemotherapy.
- Pancreatic Cancer:
NCCTG N064B: Randomized Phase II Trial of Panitumumab, Erlotinib, and Gemcitabine vs. Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma
(1_20090608_118)
In this study for untreated metastatic pancreatic adenocarcinoma, participants will be randomized to one of two arms of treatment for two cycles of treatment. A cycle is for 28 days. Depending on the response, the participant may go on for additional treatment of 2 cycles or monitoring. Participant’s blood will be closely monitored weekly; and CT scan or MRI and X-ray will be done every other cycle. Tumor, blood and stool specimens will be requested for additional research to evaluate tumor markers.
- Pediatric Cancers: Wilm's Tumor, Rhabdomyosarcoma, ALL and NHL:
COG: ACCL0731: GLUTAMIC ACID TO DECREASE VINCRISTINE TOXICITY IN CHILDREN WITH CANCER
(2_20090512_118)
Patients will be randomized to receive either 1-glutamic acid hydrochloride vs placebo along with vincristine containing chemo regimen. Depending on the disease process, participants will receive either a 4 week regimen or a 9 week regimen. Neurologic exams will be give to measure neurotoxicity
- Registry for Children with Cancer -
COG #ACCRN07: PROTOCOL FOR THE ENROLLMENT ON THE OFFICIAL COG REGISTRY, THE CHILDHOOD CANCER RESEARCH NETWORK (CCRN)
(1_20080202_118)
Any participant that is seen by a member of the COG will be asked for their interest to consent for the patient to be enrolled into the registry.
|
|
